FDA
-
Cell and Gene, CMMI, Drug shortages, DTC, FDA, Pharmacy Benefit Managers, State-based Reform, Supply Chain, Utilization ManagementAMP is WAC — 04/24/26
Read more: AMP is WAC — 04/24/26Stick a fork in me, I am done with this week. It was a busy week and then you add in a chief of staff (Eddie, the dog) that would whine every 2 hours at night to go outside to deal with a stomach issue and I’m toast. On one hand, #grateful, but ready for…
-
340B, Affordable Care Act, Alzheimer’s, Biosimilars, Cell and Gene, CMMI, FDA, Inflation Reduction Act, Medicare Part D, ObesityAMP is WAC — 03/13/26
Read more: AMP is WAC — 03/13/26The Bigger They Are, the Faster They Grow. A new white paper from Health Capital Group, sponsored by Johnson & Johnson, analyzed HRSA’s OPAIS database from 2017 through 2023 and found something many observers of the 340B program have suspected for years; size is the dominant variable. Hospitals in the top quartile by bed size…
-
340B, Biosimilars, Caught my eye, DTC, Employers, FDA, Obesity, Reference Pricing, State-based Reform, ValueAMP is WAC — 2/20/26
Read more: AMP is WAC — 2/20/26We have some new folks around these parts so quick intro. I’m Jennifer Snow. I’ve spent 25 years inside the U.S. pharmaceutical policy world, not watching it from the outside, but sitting in the meetings, reading the rules, and translating what they actually mean for the people whose drugs are on the line. I’m not…
-
340B, Caught my eye, CMMI, Drug Prices, FDA, Healthcare Costs, Inflation Reduction Act, Medicare Advantage, Medicare Negotiation, Medicare Part D, Orphan Drugs, Pharmacy Benefit Managers, Reference Pricing, ValueAMP is WAC — 1/16/26
Read more: AMP is WAC — 1/16/26In case you thought I’d leaving you hanging, today’s newsletter has a summary on GLOBE. Sphere it below? Calling it a Plan would be GENEROUS, but that’s a Whole Other Thing. On Thursday, the White House released a fact sheet urging Congress to enact President Trump’s “Great Healthcare Plan,” pitching it as a cost-cutting package…
-
340B, Caught my eye, CMMI, Drug Prices, FDA, Generics, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Medicare Transaction Facilitator, Obesity, Reference PricingAMP is WAC — 1/9/26
Read more: AMP is WAC — 1/9/26Something is bugging me this week. Okay, lots of things are bugging me this week, but the one that is relevant to this newsletter is the STAT News headline that implied it is awesome to be a pharmaceutical executive in 2026. This week, there were reports of more than 25,000 layoffs in pharma last year.…
-
340B, Alzheimer’s, Caught my eye, FDA, Healthcare Costs, Inflation Reduction Act, Medicare Negotiation, Preventative, Reference Pricing, ValueAMP is WAC — 12/12/25
Read more: AMP is WAC — 12/12/25Much of this week felt like playing catch-up from past weeks. Good timing because rumors are swirling about Most Favored Nation (MFN) demonstration releases for late next week. Comment letter fun during the holidays! For those of you who are new to these parts… welcome! I’m a health policy strategist focused on pharmaceuticals. My goal…
-
340B, Affordable Care Act, CMMI, FDA, Inflation Reduction Act, Medicaid, Medicare Part D, State-based ReformAMP is WAC — 11/21/25
Read more: AMP is WAC — 11/21/25This week felt weirdly calm – I am sure I just jinxed it. No AMP is WAC next week. If something interesting happens, I’m sure I won’t be able to help myself and will post on LinkedIn. Have a great Thanksgiving and I hope you remember that nothing will change that person at the table,…
-
Affordable Care Act, Alzheimer’s, Biosimilars, Caught my eye, Drug shortages, FDA, Medicaid, Medicare Part D, UncategorizedAMP is WAC — 11/14/25
Read more: AMP is WAC — 11/14/25How is it mid-November? I think of all of the things that need to get done by the end of the year and then try and pull out the productivity schemes (5 choices, pomodoro, eat the frog, etc.) I’ve learned over the years. The problem is that none of these create more time, just make…
Latest news
- AMP is WAC — 04/24/26
- AMP is WAC — 04/10/26
- AMP is WAC — 03/27/26
- AMP is WAC — 03/20/26
- AMP is WAC — 03/13/26
Categories
- 340B (64)
- Affordable Care Act (23)
- Alzheimer's (11)
- Biosimilars (33)
- Caught my eye (102)
- Cell and Gene (8)
- Chevron Deference (2)
- CMMI (29)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (58)
- Drug shortages (15)
- DTC (9)
- Employers (20)
- FDA (8)
- Generics (13)
- Health Equity (4)
- Healthcare Costs (41)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (69)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (24)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (78)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (28)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (49)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (32)
- Supply Chain (8)
- Tariffs (2)
- Uncategorized (9)
- Utilization Management (14)
- Vaccines (10)
- Value (18)